Generex Biotechnology (Generex Biotechnology) Current Deferred Taxes Liabilities : $1.50 Mil (As of Apr. 2021)

View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Generex Biotechnology's current deferred tax liabilities for the quarter that ended in Apr. 2021 was $1.50 Mil.

Generex Biotechnology Current Deferred Taxes Liabilities Historical Data

The historical data trend for Generex Biotechnology's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generex Biotechnology Current Deferred Taxes Liabilities Chart

Generex Biotechnology Annual Data

Trend

Jul11

Jul12

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Current Deferred Taxes Liabilities

Get a 7-Day Free Trial

1.50

Generex Biotechnology Quarterly Data
	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21
Current Deferred Taxes Liabilities	Get a 7-Day Free Trial															1.50	1.50	1.50	1.50	1.50

Generex Biotechnology Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Generex Biotechnology (Generex Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » Current Deferred Taxes Liabilities

Comparable Companies

RBSH MRPI BOM:531207 HSTC PPCB NUGX BOM:506365 CDXI IMUN RSPI

Traded in Other Exchanges

N/A

Address

10102 USA Today Way, Miramar, FL, USA, 33025

Website

https://www.generex.com

Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.

Executives

Prioletti Mark Joseph Se	director	1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr	director	450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines	other: Consultant	11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher	officer: EVP General Counsel &Secretary	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee	director	201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr.	director	33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao	officer: CFO & Treasurer	531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr.	director, officer: SVP of Research & Drug Develop	65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman	director	10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti	director	10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro	director, officer: SVP & Chief Investment Officer	10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard	officer: Chief Operating Officer	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows	officer: Chief Financial Officer	33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von	director, officer: President of Subsidiary	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt	director	555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1